Kelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership
Rhea-AI Summary
Kelyniam Global (OTC: KLYG), a custom cranial implant manufacturer, reported challenging Q1 2025 results with revenue declining 34.7% to $624,910 from $957,447 in Q1 2024. The company posted an operating loss of $(140,556) compared to a profit of $123,599 in the prior year. To address these challenges, Kelyniam appointed Alex Rivero as National Sales Director and plans to add 10 new distributors in 2025.
The company announced a significant three-year distribution agreement with Osteopore Ltd. to distribute their bioresorbable products in the U.S., including Osteostrip®, Osteoplug®, and Osteomesh®. This partnership, along with Finceramica, positions Kelyniam as a leader in regenerative medicine for cranial surgery while maintaining their commitment to 24-48 hour custom implant delivery.
Positive
- New three-year distribution agreement with Osteopore Ltd. to expand product portfolio
- Plans to onboard 10 additional distributors in 2025 to strengthen sales
- Appointment of new National Sales Director to improve sales organization
- Maintains competitive advantage with 24-48 hour custom implant delivery
Negative
- Revenue decreased 34.7% to $624,910 in Q1 2025
- Operating loss of $(140,556) compared to profit of $123,599 in Q1 2024
- Gross margin declined 36.6% to $470,940
News Market Reaction – KLYG
In the trading session that priced this news, KLYG declined 36.33%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Q1 2025 Financial Highlights (compared to Q1 2024):
- Total revenue of
$624,910 $957,447 34.7% . - Gross margin of
$470,940 $743,719 36.6% . - Operating loss of
$(140,556) $123,599
"Kelyniam experienced a challenging first quarter due to seasonal variability and the timing of surgical schedules, which delayed revenue recognition," said Ross Bjella, CEO of Kelyniam. "To address these challenges, we strengthened our sales organization by appointing Alex Rivero as National Sales Director and plan to onboard up to 10 additional distributors in 2025. Our commitment to delivering custom implants within 24-48 hours, combined with strategic partnerships, positions us for improved performance."
Strategic Partnerships: Kelyniam has entered a three-year distribution agreement with Osteopore Ltd. (ASX: OSX), a
"Our partnerships with Osteopore and Finceramica position Kelyniam as a leader in regenerative medicine in the
Desiree Webb, Kelyniam's Chief Operating and Revenue Officer said, "Osteopore's products are exceptional additions for surgeons in need of a biomimetic and bioresorbable option for areas where natural, healthy bone growth are desired. Kelyniam is laser focused on providing the best in cranial and craniofacial regenerative options, and we look forward to making great strides with Osteopore in
Osteopore's CEO, Dr. Yujing Lim said, "Kelyniam has demonstrated its ability to manufacture and distribute effectively, as shown by their record performance in 2024. We believe that working directly with Kelyniam allows us to leverage their established access to hospitals and potential customers, thereby accelerating customer access to Osteopore's products.
Kelyniam's complete financial results are available at www.kelyniam.com. The company will discuss these results and strategic initiatives at its Annual Shareholder Meeting on June 23, 2025, at 9:00 AM Central Time.
About Kelyniam Global, Inc.
Kelyniam Global, Inc. designs, manufactures, and distributes custom cranial and craniofacial implants using biocompatible materials. Known for its rapid 24-48 hour delivery, Kelyniam collaborates with surgeons and healthcare providers to improve clinical outcomes. Learn more at www.kelyniam.com.
About Osteopore Ltd.
Osteopore Ltd., based in
About Finceramica Faenza S.p.A.
Finceramica, based in Faenza,
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, including those regarding future sales, distributor expansion, and the impact of strategic partnerships, involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include economic conditions, competitive pressures, regulatory changes, and challenges in executing sales strategies, as detailed in Kelyniam's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Kelyniam undertakes no obligation to update these statements except as required by law.
View original content:https://www.prnewswire.com/news-releases/kelyniam-global-announces-q1-2025-financial-results-and-strategic-partnership-302451739.html
SOURCE Kelyniam Global Inc